Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Evoke Pharma, Inc. (Nasdaq: EVOK) has completed a follow-on offering of 5,750,000 shares at $2.50 per share, generating approximately $14.4 million in gross proceeds. The funds will be allocated for working capital, commercialization, research and development, clinical trials, and potential acquisitions. Laidlaw & Company (UK) Ltd. managed the offering under a previously filed shelf registration. This financing aims to enhance Evoke's capacity to treat gastrointestinal disorders, focusing on GIMOTI, a nasal spray for diabetic gastroparesis patients.
- Raised approximately $14.4 million to support working capital and general corporate purposes.
- Funds directed towards commercialization and research activities, potentially enhancing market position.
- Dilution of existing shareholders due to the increase in the number of shares.
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock sold pursuant to the underwriter’s full exercise of its option to purchase additional shares, at a price to the public of
Evoke intends to use the net proceeds from the offering for working capital and general corporate purposes, including funding commercialization activities, research and development activities, clinical trial expenditures, and possible acquisition of new technologies or products.
Laidlaw & Company (UK) Ltd. acted as sole book-running manager for the offering.
The offering is being conducted pursuant to a shelf registration statement (File No. 333-251614) previously filed and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to this offering were filed with the SEC and are available free of charge on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from Laidlaw & Company (UK) Ltd, Attention: Syndicate Department, 521 Fifth Avenue, New York, NY 10175, by telephone at (212) 953-4917 or by email at syndicate@laidlawltd.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s anticipated use of proceeds from the offering. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contact:
The Ruth Group
James Salierno
Tel: 973-255-8361
jsalierno@theruthgroup.com
Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com
FAQ
What was the purpose of Evoke Pharma's recent stock offering?
How much did Evoke Pharma raise from their stock offering?
What is the stock price for Evoke Pharma's recent offering?
Who managed Evoke Pharma's stock offering?
